# A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

> **NCT04457310** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 112 (actual)

## Conditions studied

- Early Course Schizophrenia Spectrum Disorder

## Interventions

- **DRUG:** CVL-562 (PF-06412562) 1 mg
- **DRUG:** CVL-562 (PF-06412562) 4 mg
- **DRUG:** CVL-562 (PF-06412562) 15 mg
- **DRUG:** CVL-562 (PF-06412562) 25 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04457310
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-02
- **Primary completion:** 2024-03-22
- **Final completion:** 2024-03-22
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04457310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04457310, "A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04457310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*